Palisade Bio (PALI) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Palisade Bio (PALI) over the past year, gaining 8.4% versus a loss of 11.9%. Over five years, PLX leads with a +120.3% price change compared with -99.9% for PALI. Palisade Bio is the larger company by market cap ($252.7 million vs $217.5 million), about 1.2 times the size.
On valuation, Palisade Bio trades at a lower trailing P/E (2.4x vs 11.7x for Protalix BioTherapeutics (DE)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PALI | PLX |
|---|---|---|
| Share price | $1.45 | $2.70 |
| Market cap | $252.69M | $217.54M |
| 1-day change | -2.03% | -0.37% |
| YTD return | -37.02% | +50.56% |
| 1-year return | -11.90% | +8.40% |
| 5-year return | -99.93% | +120.33% |
| P/E ratio (TTM) | 2.42 | 11.74 |
| Forward P/E | — | 4.35 |
| EPS (TTM) | $0.60 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.86 | $3.19 |
| 52-week low | $1.32 | $1.60 |
| Distance from 52-week high | -49.30% | -15.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +604.83% | +307.41% |
| Average volume | 2.60M | 732.64K |
| Shares outstanding | 174.27M | 80.57M |
| Employees | 14 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed PALI by 20.3 percentage points over the past year.
- Protalix BioTherapeutics (DE) trades at a higher earnings multiple (11.7x vs 2.4x trailing P/E).
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
PALI vs PLX FAQ
Which is bigger, Palisade Bio or Protalix BioTherapeutics (DE)?
Palisade Bio (PALI) is larger, with a market capitalization of $252.69M compared with $217.54M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, PALI or PLX?
PLX returned +8.40% over the past 12 months, compared with -11.90% for PALI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PALI or PLX?
PALI has the lower trailing P/E at 2.4, versus 11.7 for PLX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Palisade Bio and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.